It is substantiated by the upregulation of survivin in serum (77), synovial fluid (50), and peripheral blood mononuclear cells (PBMCs) (7) of RA patients, underpinning its potential relevance as a diagnostic biomarker and prognostic indicator in these patients (78, 79). Here, BIRC5 is linked to rheumatoid arthritis.